Are the treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) effective and safe? - A Cochrane Overview summary with commentary
Open Access
- 17 July 2019
- journal article
- research article
- Published by SAGE Publications in NeuroRehabilitation
- Vol. 44 (4) , 609-612
Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a potentially disabling health condition. To assess the effects of different pharmacological interventions used in CIPD. To summarize and to discuss the rehabilitation perspective on the published Cochrane Overview "Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overviewof systematic reviews" by Anne Louise Oaklander, et al., representing the Cochrane Neuromuscular Group. Five CSRs and 23 RCTs, reporting data on corticosteroids, plasma exchange and intravenous immunoglobulin, were considered in the overview. High quality trials investigating the combined effectiveness of drugs and exercise using ICF based outcomes should be encouraged.Keywords
This publication has 5 references indexed in Scilit:
- Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyCochrane Database of Systematic Reviews, 2017
- Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviewsCochrane Database of Systematic Reviews, 2017
- Immunotherapy in Peripheral NeuropathiesNeurotherapeutics, 2016
- Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathyCochrane Database of Systematic Reviews, 2013
- Exercise for people with peripheral neuropathyCochrane Database of Systematic Reviews, 2004